Association between LAPTM4B gene polymorphism and susceptibility to and prognosis of diffuse large B-cell lymphoma
Association between LAPTM4B gene polymorphism and susceptibility to and prognosis of diffuse large B-cell lymphoma
复制标题
LAPTM4B基因多态性与弥漫性大B细胞淋巴瘤易感性及预后的关系
DOI：
10.3892/ol.2017.7318
复制
发表时间：
2018-01-01
期刊：
影响因子：
2.9
通讯作者：
Song, Yuqin
中科院分区：
文献类型：
--
作者：
Ding, Huirong;Cheng, Xiaojing;Song, Yuqin
溶酶体蛋白跨膜413（LAPTM 4 B）是在多种类型的人类癌症中过表达的癌基因。LAPTM 4 B有两个已知的等位基因：LAPTM 4 B *1和LAPTM 4 B *2。本研究评估了LAPTM 4 B多态性与弥漫性大B细胞淋巴瘤（DLBCL）易感性及其预后之间的关系。采用聚合酶链反应（PCR）方法检测164例DLBCL患者和350例健康对照者的LAPTM 4 B基因型。采用非条件Logistic回归分析LAPTM 4 B多态性与DLBCL风险之间的关系。使用Kaplan-Meier分析计算患者生存率的差异。DLBCL组LAPTM 4 B *2等位基因频率为26.5%，对照组为24.1%，两组间差异无统计学意义（P>0.05）。与LAPTM 4 B *1/1基因型相比，LAPTM 4 B *1/2基因型[比值比（OR）=1.160; 95%置信区间（CI）=0.781-1.724]或LAPTM 4 B *2/2基因型（OR=1.446; 95% CI=0.648-3.227）病例发生DLBCL的风险略有增加。在DLBCL患者中，LAPTM 4 B *2等位基因的存在与总生存期（OS）和无病生存期（DFS）之间无显著相关性（分别为P=0.399和0.520）。然而，LAPTM 4 B *2和国际预后指数（IPI）评分为3-5的患者有OS和DFS延长的趋势（分别为P=0.126和0.109）。提示LAPTM 4 B基因多态性不是DLBCL发生的危险因素，但LAPTM 4 B *2等位基因可能是IPI评分3-5分DLBCL患者较好的预后指标。
Lysosomal protein transmembrane 413 (LAPTM4B) is an oncogene that is overexpressed in a number of various types of human cancer. There are two known alleles of LAPTM4B: LAPTM4B*1 and LAPTM4B*2. The present study assessed the association between LAPTM4B polymorphisms and the susceptibility to diffuse large B-cell lymphoma (DLBCL) and its prognosis. LAPTM4B genotypes were determined using polymerase chain reaction analysis in 164 DLBCL and 350 healthy control cases. The association between LAPTM4B polymorphisms and the risk of DLBCL was analyzed using unconditional logistic regression. Differences in patient survival were calculated using Kaplan-Meier analysis. The present study indicated no significant differences (P>0.05) in the frequency of LAPTM4B*2 alleles between DLBCL cases (26.5%) and controls (24.1%). The risk of DLBCL was slightly increased in cases with the LAPTM4B*1/2 genotype [odds ratio (OR)=1.160; 95% confidence interval (CI)=0.781-1.724] or the LAPTM4B*2/2 genotype (OR=1.446; 95% CI=0.648-3.227) compared with those with the LAPTM4B*1/1 genotype. There was no significant association between the presence of the LAPTM4B*2 allele and overall survival (OS) and disease-free survival (DFS) in patients with DLBCL (P=0.399 and 0.520, respectively). However, there was a tendency for patients with LAPTM4B*2 and International Prognostic Index (IPI) score 3-5 to have longer OS and DFS (P=0.126 and 0.109, respectively). These findings suggest that genetic polymorphisms of LAPTM4B is not a risk factor for the development of DLBCL, but the LAPTM4B*2 allele may a better prognostic indicator in patients with IPI score 3-5 in DLBCL.